Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

Completed · Phase 1

Conditions studied: Juvenile Idiopathic Arthritis

In brief

This open-label extension of the JIGSAW studies (WA28117 \[NCT01904279\] and WA28118 \[NCT01904292\]) is designed to evaluate the long-term safety and efficacy of subcutaneous (SC) tocilizumab treatment in participants with polyarticular-course and systemic juvenile idiopathic arthritis (pJIA and sJIA). Participants from the 2 JIGSAW studies will continue to receive 162 milligrams (mg) of SC tocilizumab with treatment schedule according to arthritis subtype and body weight. Participants will receive the treatment until commercial availability of the drug or for a maximum of 5 years, whichever is earlier.

Key facts

Study ID

NCT02165345

Run by

Hoffmann-La Roche

People needed

82

Starts

2014-07-16

Expected to finish

2021-11-24

Last updated by the study team

2022-02-23

Who can join

Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion of either of the JIGSAW studies, study WA28117 (for participants with pJIA) or study WA28118 (for participants with sJIA)
• Adequate disease control with the use of SC tocilizumab(TCZ)(comparable to the use of IV TCZ, if received prior to enrollment in the JIGSAW study), per clinical judgment of the investigator
• For participants of reproductive potential: agreement to remain abstinent or use of effective contraception as defined by the study protocol

You may not qualify if…

• Prior discontinuation of SC tocilizumab because of inadequate clinical response during participation in a JIGSAW study
• Poorly controlled disease (in opinion of treating physician) despite treatment with SC tocilizumab in the JIGSAW study
• Prior discontinuation of intravenous tocilizumab because of inadequate clinical response or safety events (including hypersensitivity)
• Therapy with biologic agents (except tocilizumab) in the period between completion of the JIGSAW study and screening for the current study
• Concurrent treatment with disease-modifying anti-rheumatic drugs (DMARDs) (including methotrexate), nonsteroidal anti-inflammatory drugs (NSAIDs), and oral corticosteroids is permitted at the discretion of the investigator
• Use of live or attenuated vaccines and immunosuppressants, such as cyclosporine and cyclophosphamide
• Any significant concurrent medical or surgical conditions or findings that would jeopardize the participant's safety or ability to complete the study, including but not limited to disease of the nervous, renal, hepatic, cardiac, pulmonary, gastric, or endocrine system or any infection
• History of alcohol, drug, or chemical abuse within 6 months prior to screening
• History of atypical tuberculosis (TB) or active TB requiring treatment within 2 years prior to screening
• Known human immunodeficiency virus infection or other acquired forms of immune compromise or inborn conditions characterized by a compromised immune system
• Clinical signs or symptoms of acute or chronic viral hepatitis or chronic autoimmune hepatitis arising since enrollment in the JIGSAW study
• History of concurrent serious gastrointestinal disorders, such as ulcer or inflammatory bowel disease, Crohn's disease, ulcerative colitis, or other symptomatic lower gastrointestinal conditions
• History of or current cancer or lymphoma
• Uncontrolled diabetes mellitus with elevated glycosylated hemoglobin (HbA1c), defined with the use of age-specific standards
• Any abnormal laboratory values, an elevation of hepatic transaminases ([aspartate aminotransferase [AST] or alanine aminotransferase [ALT]), lowering of neutrophil count, or thrombocytopenia attributed to tocilizumab use by investigator at screening, the participant may be enrolled; however, the initial tocilizumab dose may be delayed to adhere to the protocol risk mitigation strategy or per the investigator's clinical judgment
• Prior stem cell transplant at any time

Where it is running

• Arkansas Children's Hospital Research Institute — Little Rock, Arkansas, United States
• University of Chicago Hospital — Chicago, Illinois, United States
• Hackensack University Medical Center; Pediatric Rheumatology — Hackensack, New Jersey, United States
• Duke University — Durham, North Carolina, United States
• Cincinnati Children'S Hospital Medical Center; Division of Rheumatology — Cincinnati, Ohio, United States
• Cleveland Clinic Fndn — Cleveland, Ohio, United States
• Healthcare Research Consultants — Tulsa, Oklahoma, United States
• University of Utah; Immunology/Rheumatology/Allergy — Salt Lake City, Utah, United States
• Seattle Children's Hospital — Seattle, Washington, United States
• Hospital Gral de Niños Pedro Elizalde — Buenos Aires, Argentina
• Hospital de Ninos de la Santisima Trinidad; Hematología — Córdoba, Argentina
• Westmead Hospital; Paediatric Rheumatology — Westmead, New South Wales, Australia
• Royal Children'S Hospital; Paediatric Rheumatology — Parkville, Victoria, Australia
• Universidade Federal de Sao Paulo - UNIFES — São Paulo, São Paulo, Brazil
• Hospital das Clinicas - FMUSP — São Paulo, São Paulo, Brazil
• Alberta Children'S Hospital — Calgary, Alberta, Canada
• The Hospital for Sick Children — Toronto, Ontario, Canada
• CH de Bicêtre; Pediatrie Generale — Le Kremlin-Bicêtre, France
• Charité Campus; Virchow Klinikum Berlin — Berlin, Germany
• Uniklinikum Freiburg Zentrum für Kinder- und Jugendmedizin; Pädiatrische Infektio- u. Rheumatologie — Freiburg im Breisgau, Germany
• Asklepios Klinik; Zentrum für Allgemeine Pädiatrie und Neonatologie — Sankt Augustin, Germany
• Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina — Rome, Lazio, Italy
• Hospital Infantil de México "Federico Gomez"; Rheumatology — México, Mexico
• Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria — Monterrey, Mexico
• SI Sceintific children health center RAMS — Moscow, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.